Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

January 31, 2007

Conditions

HIV Infections

Interventions

DRUG

Pegylated interferon alfa-2a

Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment

Trial Locations (3)

Duke University Medical Center, Durham

University of California, Davis Medical Center, Sacramento

Northwestern University, Chicago

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00078442 - Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People | Biotech Hunter | Biotech Hunter